NeuroPace stock
NPCENASDAQNeuroPace, Inc., HealthcareISIN US6412881053
34Score 34 out of 100, Weak
Price and trend
42 / 100
Price history
−11% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 19% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 40).
The price is 38% below its 52-week high. Largest decline in 6 years: 95% (April 2021 to December 2022).
Chart figures for advanced users
- SMA 50$13.35
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.80
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)40
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.02
- The lowest closing price of the last twelve months.
- Resistance$19.29
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- NeuroPace, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $412.58M, is number 83 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $99.99M (up 25.1% year on year) and a loss of $21.47M.
- For fiscal 2026, analysts expect on average revenue of $100.28M (up 0.3%) and adjusted earnings per share of −$0.57.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 651 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 195% since 2020.Capital allocation 18
- High debtDebt 5.88 times equity (latest quarter), Medical (Devices) median 0.47.Stability 28
- Loss-makingLoss of $19.11M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 11.6% on the twelve months before. Revenue has grown strongly since 2019, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating −16%, net −21%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported −$0.03 (expected −$0.11)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 3.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.57−3.8%
- Revenue
- $100.28M−0.1%
- Earnings per share
- −$0.28+3.4%
- Revenue
- $121.95M−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −2.2%2026 guidance raised: revenue of $99.5 million to $101.5 million (previously $99 million to $101 million), gross margin of 82% to 83%, adjusted EBITDA loss narrowed to $7.5 million to $8.5 million (previously $8.5 million to $9.5 million).
“We are increasing full-year total revenue guidance to a range of $99.5 million to $101.5 million, compared to our previous range of $99 million-$101 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Morrell MarthaSale
15 Dec 2025, CHIEF MEDICAL OFFICER
- Shares
- 25,000
- Price
- $15.97
- Value
- $399,250
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at NeuroPace
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Avita MedicalRCEL $533.99M44
- CellaVisionCEVI.ST $486.32M80
- Revenio GroupREG1V.HE $471.42M47
- Metall ZugMETN.SW $460.48M38
- CerusCERS $428.14M36
- ImplanticaIMP-A-SDB.ST $393.83M49
- StratecSBS.DE $353.7M52
- CapsoVisionCV $333.63M41
ETFs that hold NeuroPace
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.